The Disease in the Middle

Mixed connective tissue disease borrows from lupus, scleroderma and myositis, and is held together by one antibody. What it is, how it is diagnosed, why the lungs matter most, and why, fifty years on, doctors still argue about whether it exists.

In 1972 Gordon Sharp, Halsted Holman and their colleagues described 25 patients who did not fit. They had Raynaud’s phenomenon, the fingers that turn white and blue in the cold; swollen fingers; a stiff oesophagus; aching or inflamed joints. Some features were those of lupus, some of systemic sclerosis (scleroderma), some of the muscle disease myositis. What they shared was a high level of one antibody, against a protein that could be extracted from cell nuclei and destroyed by an enzyme that breaks down RNA. The authors called the condition “an apparently distinct rheumatic disease syndrome”: mixed connective tissue disease, MCTD.[1][2][3]

The earlier essays here followed the immune system’s brakes. The Second Lock told how regulatory T cells keep it from attacking the body and how autoimmune disease can become a state that sustains itself; The Brakes Released told the same story from the side of cancer. MCTD is a good test of both. It is rare, it is hard to define, and almost everything about it, from its name to its treatment, rests on smaller numbers than the diseases it resembles. This essay sets out what is known, with the figures from the cohorts that have followed patients for decades, and where the uncertainty lies.

3.8adults in every 100,000 living with MCTD in Norway, the best-counted population; 3.3 women for every man

99%of patients in the Norwegian cohort had Raynaud’s phenomenon; 94% had puffy hands

9 of 22deaths in a Hungarian cohort of 280 patients were from high blood pressure in the lungs, the leading cause

0completed randomised trials of any treatment in MCTD alone were found; one that began was stopped with four MCTD patients enrolled

The name

Fifty years of argument

The 1972 description came with a promise. A year earlier, the same group had reported that the highest levels of the antibody were found in patients with “a mixed connective tissue disease syndrome with features of SLE, scleroderma, and myositis”, notable “for the absence of renal disease and for a striking responsiveness to corticosteroid therapy”.[4] A disease with a single marker, spared kidneys and a good response to steroids would have been good news for patients and doctors alike.

Fig. 1 — A disease in the overlap. MCTD combines features of lupus, systemic sclerosis and myositis, and is defined by antibodies against U1-RNP. A sketch, not a measurement: most patients have some features of each, not all of all three.

It did not last. When the original 25 patients were re-examined eight years later, eight had died, three could not be traced, and most of the rest, by the account of a 2020 review, had evolved into a well-defined disease or an overlap; some had needed heavy immunosuppression, and the antibody had not been high in all of them when first tested.[2] Critics have since argued that MCTD is an early or undifferentiated stage of lupus or systemic sclerosis, not a disease of its own.

The best answer comes from following patients for a long time. In Norway, where a nationwide study had found 147 adult patients, a prevalence of 3.8 per 100,000 adults and a mean age at diagnosis of 38,[5] 118 patients were followed for a mean disease duration of 17 years. Only 14, 12 per cent, developed another well-defined rheumatic disease. The authors concluded that MCTD is “a relatively stable disease entity” that “runs a milder course than systemic lupus erythematosus and systemic sclerosis”.[6] A cohort in Missouri, from Sharp’s own group, reported in 1999 that the disease “rarely evolved into” lupus or systemic sclerosis.[7]

Fig. 2 — Does it turn into something else? One dot per patient in the Norwegian cohort, after a mean disease duration of 17 years (Reiseter et al. 2017). A French cohort, counting differently, found that 34% progressed over eight years (see text).

A French cohort of 324 patients, published in 2025, found more change: over eight years, 34.3 per cent progressed to a defined connective tissue disease, most often systemic sclerosis (15.4 per cent) or lupus (12.3 per cent), and 90 per cent met the criteria for very early systemic sclerosis at diagnosis.[8] The cohorts used different definitions and different follow-up, and the gap between 12 and 34 per cent is in part a gap between what each counted as a new disease. The fair summary is that for most patients the label holds, and for a substantial minority it is a stage on the way to something else.

What it looks like

Cold fingers, puffy hands

Almost everyone with MCTD has Raynaud’s phenomenon, and most have puffy, swollen hands. In the 104 Norwegian patients whose disease stayed MCTD, 99 per cent had Raynaud’s and 94 per cent puffy hands; three-quarters had arthritis, a third myositis, and a third interstitial lung disease, scarring of the lung tissue (Figure 3). Puffy hands predicted that the disease would stay MCTD rather than evolve, with an odds ratio of 7.[6] A nationwide Japanese study of 249 patients, published in 2026, found Raynaud’s or swollen hands in all of them; 93 per cent were women, 32.9 per cent had major organ involvement, 12.8 per cent pulmonary arterial hypertension, and 29 per cent were classed as severe.[9]

Fig. 3 — How often each feature appears. Share of the 104 Norwegian patients whose disease stayed MCTD who had each feature at some point (Reiseter et al. 2017, Table 2). Sclerodactyly is tightening of the skin of the fingers; low white cell and platelet counts are blood findings.

There is also a pattern of severity. A Hungarian group sorted 201 patients, followed for an average of 12.5 years, into three groups by their features. In one, 56 per cent had pulmonary arterial hypertension and survival was the worst; in another, almost all had interstitial lung disease, with myositis and a stiff oesophagus; in the third, the joints dominated.[10] The name covers several diseases of different severity, held together by a shared antibody.

Diagnosis

Four sets of rules, none official

Unlike lupus, systemic sclerosis and myositis, MCTD has no classification criteria from the American College of Rheumatology and EULAR, the European rheumatology association.[11] Four sets of diagnostic criteria have been used since the 1980s, named after their authors: Sharp, Alarcón-Segovia, Kasukawa and Kahn. All require the antibody against U1-RNP; they differ in which features they add. Alarcón-Segovia’s, for example, require a high level of the antibody, Raynaud’s phenomenon and at least two of swollen hands, synovitis and myositis.[11]

Fig. 4 — Four ways to diagnose MCTD, tested on the same patients. Sensitivity (the share of patients with MCTD that each set of criteria identifies) against specificity (the share of patients with other diseases it correctly excludes), with a rheumatologist’s clinical diagnosis as the reference, in 291 patients tested in India, 111 of them with MCTD (John et al. 2020). The vertical axis starts at 85.

When a group in India tested all four on the same 291 patients, against the clinical diagnosis, Kasukawa’s criteria caught the most patients (77.5 per cent), while Alarcón-Segovia’s and Kahn’s excluded others best (99.4 per cent) at the cost of missing a third to a half of the patients (Figure 4).[12] In 2019 a Japanese committee issued revised criteria in four parts: common features such as Raynaud’s and puffy fingers; the antibody; characteristic organ involvement, namely pulmonary arterial hypertension, aseptic meningitis or trigeminal neuropathy, a disorder of a facial nerve; and overlapping features of lupus, systemic sclerosis and myositis. “Even if the overlapping manifestations are absent, MCTD can be diagnosed based on the presence of the characteristic organ involvement.”[13]

So the same patient can have MCTD under one set of rules and not under another, and the numbers in this essay depend on which set each study used. The Norwegian prevalence was similar under three of them, which is some reassurance.[5]

The target

An antibody against the cell’s own editor

The antibody that defines MCTD recognises U1-RNP, a small particle in the nucleus made of an RNA molecule, U1 RNA, and several proteins; the main targets are the proteins called 70K, A and C.[14] The particle is part of the machinery that cuts and splices newly made RNA before it is translated into protein, one of the most basic jobs in the cell. Why would the immune system attack it?

Three findings point towards an answer. First, when a cell dies by apoptosis, the 70K protein is cut by caspase-3, one of the enzymes of cell death, and one of the main targets of patients’ antibodies is present only on that apoptotic form.[15][16] The immune system may first meet the protein in modified form, in the debris of dying cells. Second, the U1 RNA in the particle is itself an alarm signal. It triggers innate immune sensors, in particular TLR7, which normally detects the RNA of viruses; immune complexes of patients’ antibodies with the particle make dendritic cells release interferon, a response that “required the presence of intact U1RNA and was largely dependent on Tlr7”.[17][18] In the terms of the primer in The Second Lock, the target carries its own second signal. Third, genes matter: in Norway the HLA variant DRB1*04:01 was nearly three times more common in patients than in controls (odds ratio 2.82), and other variants were linked with lung fibrosis.[19]

Mice put the pieces together. Mice carrying the human HLA-DR4 gene and immunised with the 70K protein made antibodies against it, and half developed lung disease resembling that of MCTD.[20] And the scurfy mice of The Second Lock, which lack regulatory T cells because their Foxp3 gene is broken, make antibodies against U1-RNP as their “most common target antigen”, together with myositis: in the authors’ words, “features of mixed connective tissue disease”.[21] Take the second lock away, and this is one of the diseases that appears.

The antibody is not unique to MCTD. It is found in about a quarter to a third of patients with lupus, depending on the cohort,[22] and in The Second Lock’s chart of the antibodies that appear years before a lupus diagnosis, anti-RNP was present in 26 per cent of the US service members who later developed lupus, about a year before diagnosis on average.[23] What sets MCTD apart is a high level of this antibody, in a particular pattern of features, without the antibodies that mark lupus or systemic sclerosis more specifically.

The lungs

Where the danger is

For most patients MCTD is a chronic disease of the hands, joints and muscles. What decides who dies is mostly the lungs. In the Norwegian cohort, 52 per cent of 126 patients had abnormal lung CT scans after a mean of nine years of disease, and 35 per cent had fibrosis, severe in 19 per cent. Over the next 4.2 years, 3.3 per cent of patients with a normal scan died, against 20.8 per cent of those with severe fibrosis.[24] In a later follow-up, interstitial lung disease was present in 41 per cent and progressed in 19 per cent; higher antibody levels, an antibody called anti-Ro52, male sex and the absence of arthritis predicted progression.[25]

Fig. 5 — Lung scarring and survival. Share of 126 Norwegian patients who died within a mean of 4.2 years, by their lung CT at the start (Gunnarsson et al. 2012).

The second danger is pulmonary arterial hypertension, high pressure in the arteries that carry blood through the lungs, which strains the right side of the heart. How common it is depends on the study. In the Norwegian cohort it was found in only 3.4 per cent of 147 patients over 5.6 years, “much lower than expected from previous studies”, but three of those five patients died.[26] A 2023 meta-analysis of eight studies with 983 patients put the pooled prevalence at 12.5 per cent, with large differences between studies and a decline over time.[27] In the Hungarian cohort of 280 patients followed since 1979, it was the leading cause of death: 9 of 22 deaths, ahead of cardiovascular disease (7), infections (3) and a rare clotting disorder (3).[28]

Fig. 6 — What patients died of. The 22 deaths among 280 Hungarian patients with MCTD followed from 1979 to 2011 (Hajas et al. 2013).

Overall survival is good. In the same Hungarian cohort, 98 per cent of patients were alive five years after diagnosis, 96 per cent at ten and 88 per cent at fifteen (Figure 7). Antiphospholipid antibodies, which are linked with blood clots, raised the risk of death.[28]

Fig. 7 — Survival after diagnosis in 280 Hungarian patients (Hajas et al. 2013). Only the three published points are shown, joined by a dashed line; the vertical axis starts at 80.

Treatment

Borrowed evidence

There is no treatment designed for MCTD, and almost no trial evidence in it. Searches of the medical literature and of the US trial registry for this essay found no completed randomised trial in MCTD alone. The one randomised trial with an MCTD group, a test by Novartis of MHV370, a drug that blocks TLR7 and TLR8, the very sensors that U1 RNA triggers, was stopped by the sponsor in 2023 after enrolling four patients with MCTD, two on the drug and two on placebo.[29] Doctors therefore treat the features, borrowing what works in the neighbouring diseases. The Norwegian patients had received nearly every drug in the rheumatologist’s cabinet, from anti-inflammatories, steroids and hydroxychloroquine to methotrexate, azathioprine, cyclophosphamide, mycophenolate, TNF blockers and rituximab, along with drugs that widen blood vessels for Raynaud’s and for the lungs.[6]

For the lungs the evidence is a little better, because MCTD is studied together with other connective tissue diseases. The RECITAL trial compared rituximab with cyclophosphamide in 101 patients with lung disease from scleroderma, myositis or MCTD; lung function improved in both groups, with no significant difference.[30] A joint guideline from the European Respiratory Society and EULAR, published in 2026, recommends that “all patients with MCTD should be screened for ILD using HRCT”, a high-resolution CT scan of the lungs, and suggests immunosuppression for MCTD lung disease, while noting that the certainty of the evidence is very low.[31] For pulmonary arterial hypertension in connective tissue disease, starting with two drugs at once worked better than one in an analysis of 187 patients from a large trial, and Japanese registry data suggest that early immunosuppression may help in MCTD, lupus and Sjögren’s disease, though that evidence is observational.[32][33]

The new treatments of the earlier essays have barely reached MCTD. Rituximab has been reported in single cases; so has anifrolumab, which blocks the receptor for the interferon that U1 RNA sets off.[34] No report of CAR-T cells in MCTD was found, although the patients in the lupus, systemic sclerosis and myositis trials described in The Second Lock have the same kind of antibody-driven disease.

Children and markers

Young patients, new antibodies

MCTD can begin in childhood; a 2026 French study cites estimates that juvenile disease accounts for 7 to 23 per cent of cases. Among its 47 patients, mostly girls with a median age at onset of 14, remission was more common than in adults, 61.7 against 44.0 per cent, but more than a third progressed to another connective tissue disease.[35] In Norway, 55 people with juvenile MCTD were followed for a mean of 16 years: all had Raynaud’s, 94 per cent arthritis and 58 per cent lung involvement; two-thirds still had active disease and 65 per cent had some lasting organ damage.[36]

The search for better markers goes on. Among 158 patients with anti-U1-RNP antibodies, antibodies against a second nuclear complex, SMN, were found in 36 per cent of those with MCTD, against 8 per cent with lupus and 12 per cent with systemic sclerosis; they were associated with pulmonary hypertension and lung disease, and all three early deaths in the study were in patients who had them.[37] If confirmed, such an antibody could identify early the patients whose lungs need the closest watching.

Coda

What is known and what is not

Established

MCTD is rare (about 4 adults in 100,000 in Norway), mostly affects women, and is defined by antibodies against U1-RNP, with Raynaud’s phenomenon and swollen hands in almost all patients. Lung disease and pulmonary arterial hypertension account for most deaths. Long-term survival is high.

Strong evidence

In long-term cohorts most patients keep the diagnosis, though a minority, 12 to 34 per cent depending on the study, develop another defined disease. U1 RNA triggers innate immune sensors, and an HLA-DR4 variant raises the risk.

Uncertain

Which diagnostic criteria to use; how common pulmonary hypertension really is (3 to 13 per cent across studies); whether new antibodies such as anti-SMN predict severe disease.

Untested

Almost every treatment: no completed randomised trial in MCTD alone, and no reports of CAR-T cells.

MCTD is what the immune system’s mistakes look like when they fall between categories. The target is part of the cell’s own machinery; the trigger may be the cell’s own RNA, which the immune system takes for a virus’s; the brake, as the scurfy mouse shows, is the one the 2025 Nobel Prize was about. Fifty years after Sharp, the disease is better described than understood, and much better described than treated. Because it is rare, the evidence comes from a few long cohorts in Norway, Hungary, Missouri, France and Japan, and from what works in its larger neighbours. The plainest facts in this essay may also be the most useful: most patients live long lives, and the lungs are what needs watching.

Open threads

Where this could go

A shared definition. Lupus, systemic sclerosis and myositis each have international classification criteria; MCTD does not. Until it does, studies count different patients, and treatment trials are hard to design.

Resetting, not suppressing. If CD19 CAR-T cells can reset lupus and systemic sclerosis, the same logic would apply to a disease driven by antibodies against U1-RNP. A small series in MCTD, with careful attention to the lungs, would be the natural next step.

Blocking the alarm. U1 RNA triggers TLR7. The first trial of a TLR7 blocker that included MCTD stopped early; MCTD is the disease in which that mechanism is clearest.

On method and tools

This essay was researched and written with Claude Opus 5.5 (Anthropic): human specification, editorial direction and critical review; machine research, drafting and figure generation. The question came from Luis, after the two essays on the immune system’s brakes. A research agent (Claude) gathered the sources, and every reference was then checked against PubMed. For most studies the figures and quotations come from the abstracts; Reiseter et al. (2017), Alves & Isenberg (2020), John et al. (2020), Ferrara et al. (2023) and the 2026 ERS/EULAR guideline were read in their open-access full text. The 1972 paper by Sharp et al. and the 1980 re-examination of its patients have no indexed abstract and are reported through the 2020 review by Alves & Isenberg. The figures are drawn by scripts/mctd.py from the published numbers named in their captions; there is no model in this essay. The cover is a drawing, not data. This essay describes what studies have found; it is not medical advice.

Authored by: Luis Matos Ferreira — Physicist, Developer, Writer

Related essays on this blog

1. The Second Lock — regulatory T cells, autoimmune disease, prevention, and treatments that reset the immune system.
2. The Brakes Released — the same brakes released against cancer, and the autoimmunity that follows.
3. The Second Reader — what AI is and is not doing in medicine.

Sources

1. G. C. Sharp, W. S. Irvin, E. M. Tan, R. G. Gould & H. R. Holman, “Mixed connective tissue disease — an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)”, American Journal of Medicine 52, 148–159 (1972); no abstract is indexed, and the paper’s contents are reported here from the review by Alves & Isenberg, doi.org.
2. M. R. Alves & D. A. Isenberg, “‘Mixed connective tissue disease’: a condition in search of an identity”, Clinical and Experimental Medicine 20, 159–166 (2020); also the source for the 1980 re-examination of the original patients (Nimelstein et al., Medicine 59, 239–248), which was not consulted, doi.org.
3. US National Library of Medicine, Medical Subject Headings, “Mixed Connective Tissue Disease” (D008947), scope note, id.nlm.nih.gov.
4. G. C. Sharp, W. S. Irvin, R. L. LaRoque et al., “Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy”, Journal of Clinical Investigation 50, 350–359 (1971), doi.org.
5. R. Gunnarsson, Ø. Molberg, I.-M. Gilboe & J. T. Gran, “The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients”, Annals of the Rheumatic Diseases 70, 1047–1051 (2011), doi.org.
6. S. Reiseter, R. Gunnarsson, J. Corander et al., “Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study”, Arthritis Research & Therapy 19, 284 (2017); feature frequencies from Table 2, doi.org.
7. M. A. Burdt, R. W. Hoffman, S. L. Deutscher et al., “Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings”, Arthritis & Rheumatism 42, 899–909 (1999), doi.org.
8. K. Chevalier, B. Thoreau, M. Michel et al., “Unravelling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum”, RMD Open 11, e006145 (2025), doi.org.
9. S. Kubo, Y. Kanda, H. Kameda et al., “Clinical characteristics and severity classification in mixed connective tissue disease: a nationwide retrospective study”, Rheumatology (Oxford) 65, keag577 (2026), doi.org.
10. P. Szodoray, A. Hajas, L. Kardos et al., “Distinct phenotypes in mixed connective tissue disease: subgroups and survival”, Lupus 21, 1412–1422 (2012), doi.org.
11. C. A. Ferrara, G. La Rocca, G. Ielo et al., “Towards early diagnosis of mixed connective tissue disease: updated perspectives”, ImmunoTargets and Therapy 12, 79–89 (2023), doi.org.
12. K. J. John, M. Sadiq, T. George et al., “Clinical and immunological profile of mixed connective tissue disease and a comparison of four diagnostic criteria”, International Journal of Rheumatology 2020, 9692030 (2020), doi.org.
13. Y. Tanaka, M. Kuwana, T. Fujii et al., “2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases”, Modern Rheumatology 31, 29–33 (2021), doi.org.
14. P. Migliorini, C. Baldini, V. Rocchi et al., “Anti-Sm and anti-RNP antibodies”, Autoimmunity 38, 47–54 (2005), doi.org.
15. L. Casciola-Rosen, D. W. Nicholson, T. Chong et al., “Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death”, Journal of Experimental Medicine 183, 1957–1964 (1996), doi.org.
16. E. L. Greidinger, M. F. Foecking, J. Magee et al., “A major B cell epitope present on the apoptotic but not the intact form of the U1-70-kDa ribonucleoprotein autoantigen”, Journal of Immunology 172, 709–716 (2004), doi.org.
17. R. W. Hoffman, T. Gazitt, M. F. Foecking et al., “U1 RNA induces innate immunity signaling”, Arthritis & Rheumatism 50, 2891–2896 (2004), doi.org.
18. E. Savarese, O. W. Chae, S. Trowitzsch et al., “U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7”, Blood 107, 3229–3234 (2006), doi.org.
19. S. T. Flåm, R. Gunnarsson, T. Garen et al., “The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases”, Rheumatology (Oxford) 54, 528–535 (2015), doi.org.
20. E. L. Greidinger, Y. Zang, K. Jaimes et al., “A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen”, Arthritis & Rheumatism 54, 661–669 (2006), doi.org.
21. O. K. Yilmaz, S. Haeberle, M. Zhang et al., “Scurfy mice develop features of connective tissue disease overlap syndrome and mixed connective tissue disease in the absence of regulatory T cells”, Frontiers in Immunology 10, 881 (2019), doi.org.
22. A. Dima, C. Jurcut, C. Baicus et al., “The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease”, Rheumatology International 38, 1169–1178 (2018), doi.org.
23. M. R. Arbuckle, M. T. McClain, M. V. Rubertone et al., “Development of autoantibodies before the clinical onset of systemic lupus erythematosus”, New England Journal of Medicine 349, 1526–1533 (2003), doi.org.
24. R. Gunnarsson, T. M. Aaløkken, Ø. Molberg et al., “Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study”, Annals of the Rheumatic Diseases 71, 1966–1972 (2012), doi.org.
25. S. Reiseter, R. Gunnarsson, T. Mogens Aaløkken et al., “Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study”, Rheumatology (Oxford) 57, 255–262 (2018), doi.org.
26. R. Gunnarsson, A. K. Andreassen, Ø. Molberg et al., “Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature”, Rheumatology (Oxford) 52, 1208–1213 (2013), doi.org.
27. A. B. Hassan, R. F. Hozayen, Z. S. Mustafa et al., “The prevalence of pulmonary arterial hypertension in patients with mixed connective tissue disease: a systematic review and meta-analysis”, Clinical and Experimental Rheumatology 41, 2301–2311 (2023), doi.org.
28. A. Hajas, P. Szodoray, B. Nakken et al., “Clinical course, prognosis, and causes of death in mixed connective tissue disease”, Journal of Rheumatology 40, 1134–1142 (2013), doi.org.
29. ClinicalTrials.gov, NCT04988087, “A study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjögren’s syndrome (SjS) or mixed connective tissue disease (MCTD)” (Novartis); status: terminated, sponsor decision, clinicaltrials.gov.
30. T. M. Maher, V. A. Tudor, P. Saunders et al., “Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial”, The Lancet Respiratory Medicine 11, 45–54 (2023), doi.org.
31. K. M. Antoniou, O. Distler, A. M. Gheorghiu et al., “ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease”, European Respiratory Journal 67, 2402533 (2026), doi.org.
32. J. G. Coghlan, N. Galiè, J. A. Barberà et al., “Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial”, Annals of the Rheumatic Diseases 76, 1219–1227 (2017), doi.org.
33. Y. Tamura, Y. Tamura, R. Takemura et al., “Immunosuppressive therapy for pulmonary arterial hypertension associated with connective tissue diseases: insights from Japanese registry”, Advances in Therapy 42, 6103–6117 (2025), doi.org.
34. N. Italiano, F. M. Perrotta, M. Fatica et al., “Anifrolumab as a therapeutic option in mixed connective tissue disease with autoimmune cytopenia: a case report and narrative review of the literature”, Reumatismo 78 (2026), doi.org.
35. K. Chevalier, B. Bader-Meunier, I. Kone-Paut et al., “Juvenile-onset mixed connective tissue disease: a multicenter retrospective cohort study”, Seminars in Arthritis and Rheumatism 76, 152889 (2026), doi.org.
36. S. O. Hetlevik, B. Flatø, M. Rygg et al., “Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study”, Annals of the Rheumatic Diseases 76, 159–165 (2017), doi.org.
37. Y. Todoroki, M. Satoh, S. Kubo et al., “Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease”, Rheumatology (Oxford) 63, 1068–1075 (2024), doi.org.